The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.
Michael J. Seider
No relevant relationships to disclose
Stephanie Shook
No relevant relationships to disclose
Corey J. Langer
No relevant relationships to disclose
Gwen Wyatt
No relevant relationships to disclose
William F. Demas
No relevant relationships to disclose
Afshin Rashtian
No relevant relationships to disclose
Cathy L Clausen
No relevant relationships to disclose
Jerry Derdel
No relevant relationships to disclose
Sean F Cleary
No relevant relationships to disclose
Christopher A. Peters
No relevant relationships to disclose
Ashok Ramalingam
No relevant relationships to disclose
James E. Clarkson
No relevant relationships to disclose
Michael B. Tomblyn
No relevant relationships to disclose
Rachel Rabinovitch
No relevant relationships to disclose
Lisa A. Kachnic
No relevant relationships to disclose
Lawrence B. Berk
No relevant relationships to disclose